BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
CLSA downgrades Lupin to underperform
Lupin is likely to remain in a range till US concerns subside. Repeat observations from US Food and Drug Administration are a key risk for delays. Goa plant, which got observation from FDA, has a significant number of pending approvals.